Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 1156 AL 1170

Association Between Ergot-Derived Dopamine Agonists and Valvular Heart Disease: A Systematic Review and Meta-Analysis

Hammad A, Ananthaneni S, Khraisat O, Ahmad A, Munshi H, Al-Ashqar R, Patel R, Goparaju P, Dajani AR, Shamoon F, Vasudev R.

Cardiol Rev. 2026 Jul 9. doi: 10.1097/CRD.0000000000001387. Online ahead of print.

Monitoring nocturnal movement and sleep in Parkinson's disease: a systematic review of movement sensors

Mijnsbergen MD, van Tilborg PJ, Kerckhaert L, Fronczek R, van Hilten BJ, Hepp DH, Weijer RHA.

NPJ Parkinsons Dis. 2026 Jul 9. doi: 10.1038/s41531-026-01431-7. Online ahead of print.

Emerging mechanisms and targeted therapy of PANoptosis in neurological diseases

Tang Q, Xu M, Xiao X, Cao J, Yang W.

Rev Neurosci. 2026 Jul 10. doi: 10.1515/revneuro-2026-0062. Online ahead of print.

Continuous Intrajejunal Levodopa-Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series

Andrés VV, Amory J, Lucie H, Guillemette C, Laetitia L, Aurélie B, Mylène D, Céline B, Solène F, Mathilde R, Salomé P.

Mov Disord Clin Pract. 2026 Jul 9:10.1002/mdc3.70738. doi: 10.1002/mdc3.70738. Online ahead of print.

Surgical Outcomes of Degenerative Cervical Myelopathy in Patients with Parkinson Disease: A Systematic Review

Takenaka S, Ishiguro H, Yoshii T, Yamada K, Takasawa E, Nori S, Kato S, Kitamura K, Furuya T, Nakashima H, Wakao N, Nakanishi K, Fujiwara Y, Yoshida M, Watanabe M, Chikuda H.

Global Spine J. 2026 Jul 10:21925682261468270. doi: 10.1177/21925682261468270. Online ahead of print.

Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?

Di Lazzaro G, Cimmino AT, Bentivoglio AR, Stocchi F, Calabresi P.

J Parkinsons Dis. 2026 Aug;16(5):864-876. doi: 10.1177/1877718X261431104. Epub 2026 Jul 10.

Dystrophic changes of nigrostriatal axons harboring a Synj1 Parkinson mutation suggest catastrophic failure of endocytic mechanisms

Wu Y, Xu P, Moran J, Xu CS, Hayworth KJ, Cao M, Shao L, Surmeier DJ, Hess HF, Camilli P.

bioRxiv [Preprint]. 2026 Jun 29:2026.06.24.733515. doi: 10.64898/2026.06.24.733515.

The NORAD-pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes

Zemke JE, Huang G, Starr E, Broder M, Marsh J, Renganathan A, Phillips B, Marsh TW, Minaya M, Cruchaga C, Iyer AK; Dominantly Inherited Alzheimer Network; Karch CM.

bioRxiv [Preprint]. 2026 Jul 3:2026.06.30.735697. doi: 10.64898/2026.06.30.735697.

R1398 is the GTP-γ-phosphate sensor that drives the ROC G-domain switching mechanism unique to Parkinson's disease-associated LRRK2

Park Y, Wu CX, Yadav RK, Tennessen K, Hoang NC, Hoang CW, Reed X, Huang X, Cookson MR, Nichols RJ, Liao J, Hoang QQ.

Res Sq [Preprint]. 2026 Jul 1:rs.3.rs-10121216. doi: 10.21203/rs.3.rs-10121216/v1.

Prevalent versus incident progressive supranuclear palsy: An analysis of the frequencies of neuropathological and clinical features at U.S. Alzheimer's Disease Research Centers indicate a relatively common tauopathy of aging

Cushing BJ, Shahidehpour RK, Abner EL, Jicha GA, Neltner JM, Breig MK, Teodorescu KL, Neltner AM, Coskun EP, Kovacs GG, Nelson PT.

Res Sq [Preprint]. 2026 Jul 1:rs.3.rs-10119056. doi: 10.21203/rs.3.rs-10119056/v1.

LRRK2 in Focus: A Global Browser Linking Genetic Diversity to Functional Effects

Grant SM, van Midden V, Fernandez-Toledo E, Cham M, Sammler E, Alessi DR; Global Parkinson’s Genetics Program; Morris HR, Blauwendraat C, Singleton AB, Lange LM.

medRxiv [Preprint]. 2026 Jul 4:2026.07.01.26357034. doi: 10.64898/2026.07.01.26357034.

Exercise modulation of BDNF/TrkB signaling in Parkinson's disease: an evidence-calibrated review of neuroprotective mechanisms, biomarker limitations, and translational gaps

Chen C, Liu K, Xiang M, Zhang X.

Front Neurol. 2026 Jun 25;17:1860227. doi: 10.3389/fneur.2026.1860227. eCollection 2026.

From Air to Brain: Environmental Nanoparticles as Modifiable Risk Factors for Neurodevelopmental, Neurodegenerative, and Mental Disorders

Hermosillo-Abundis C, Arias-Carrion O, Contreras-Ibáñez C, Mendez-Rojas MA.

ACS Omega. 2026 Jun 20;11(26):38267-38287. doi: 10.1021/acsomega.5c12354. eCollection 2026 Jul 7.

Targeting IL-33 in Precision Neuroimmunology: Cellular Mechanisms and Therapeutic Strategies for CNS Disorders

Li L, Wang S, Duan L, Zhang L, Yan H, Zhu Y, Tao L, Gao Y.

J Neuroimmune Pharmacol. 2026 Jul 10;21(1):34. doi: 10.1007/s11481-026-10302-0.

Parkinson Disease: Think Before You Step

Perlmutter JS, Norris SA.

Neurology. 2026 Aug 11;107(3):e218342. doi: 10.1212/WNL.0000000000218342. Epub 2026 Jul 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias